AstraZeneca: FDA Places Anti Blood Cancer Trials On Hold

Features Dow Jones Newswires

AstraZeneca PLC (AZN.LN) Thursday said the U.S. Food and Drug Administration has put some of its blood cancer treatment trials on hold after identifying risks in other drug trials that also use an anti-PD-L1 agent.

Continue Reading Below

Shares at 1146 GMT, up 47.5pence, or 1%, at 4624 pence valuing the company at GBP58.1 billion.

-Write to Rory Gallivan at; Twitter: @RoryGallivan

(END) Dow Jones Newswires

September 07, 2017 08:03 ET (12:03 GMT)